CancerDrs Find care

Brain Cancer clinical trials in Arizona

25 actively recruiting brain cancer trials at 6 sites across Arizona.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Arizona:
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
Phase 3 Recruiting Academic/Other

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…

Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Arizona:
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Arizona:
  • Banner Children's at Desert — Mesa, Arizona
  • Phoenix Childrens Hospital — Phoenix, Arizona
Phase 3 Recruiting Industry

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Phoenix, Arizona
  • Barrow Neurological Institute — Phoenix, Arizona
  • Phoenix Childrens Hospital — Phoenix, Arizona
  • Mayo Clinic Arizona — Phoenix, Arizona
Phase 3 Recruiting Industry

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade g…

Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05566795
Sites in Arizona:
  • Phoenix Children's Hospital — Phoenix, Arizona
Phase 3 Recruiting Industry

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…

Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Arizona:
  • Mayo Clinic Hospital — Phoenix, Arizona
Phase 3 Recruiting Industry

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…

Sponsor: InSightec
NCT ID: NCT05317858
Sites in Arizona:
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Phase 3 Recruiting Academic/Other

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a…

Sponsor: Mayo Clinic
NCT ID: NCT03750227
Sites in Arizona:
  • Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 1, Phase 2 Recruiting NIH

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Arizona:
  • Banner Children's at Desert — Mesa, Arizona
  • Phoenix Childrens Hospital — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Arizona:
  • Phoenix Childrens Hospital — Phoenix, Arizona
Phase 2 Recruiting Industry

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Research…

Sponsor: Diakonos Oncology Corporation
NCT ID: NCT06805305
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
Phase 1, Phase 2 Recruiting Industry

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Arizona:
  • Mayo Clinic Scottsdale — Scottsdale, Arizona
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard…

Sponsor: Myosin Therapeutics Inc.
NCT ID: NCT07185880
Sites in Arizona:
  • Mayo Clinic Hospital — Phoenix, Arizona
Phase 2 Recruiting Academic/Other

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study

This phase II trial studies the clinical outcomes of hypofractionated radiation therapy in patients with diffuse midline gliomas. This study aims to change the way radiation is delivered, from giving 6 weeks of radiation all at once to giv…

Sponsor: Mayo Clinic
NCT ID: NCT05077735
Sites in Arizona:
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Phase 2 Recruiting Academic/Other

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

The goal of this diagnostic intervention clinical trial is to compare 18F-Fluciclovine uptake within brain lesions over 60 minutes compared with standard of care positive histology confirmation or confirmation MRI images. The main question…

Sponsor: University of Arizona
NCT ID: NCT06055790
Sites in Arizona:
  • Arizona Cancer Center at UMC North/University Medical Center — Tucson, Arizona
Phase 1, Phase 2 Recruiting Academic/Other

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 pat…

Sponsor: University of Arizona
NCT ID: NCT06814496
Sites in Arizona:
  • Arizona Cancer Center at UMC North/University Medical Center — Tucson, Arizona
EARLY Phase 1 Recruiting Academic/Other

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma (HGG) and newly-diagnosed glioblastoma (nGBM). BDTX-1535 was designed to block a growth signal important to some cancers. …

Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
NCT ID: NCT06072586
Sites in Arizona:
  • Chandler Regional Medical Center — Chandler, Arizona
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other

Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO criteria) targeting the mTOR pathway. Eligible participants will …

Sponsor: Nader Sanai
NCT ID: NCT05773326
Sites in Arizona:
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

This will be an open-label Phase 0/1 study that will enroll approximately 15 participants, 9 participants with recurrent WHO Grade 4 glioma (rGBM) and 6 participants with brain metastases, who will receive the investigational drug risvutat…

Sponsor: Nader Sanai
NCT ID: NCT07268053
Sites in Arizona:
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other

Study of Sonodynamic Therapy in Participants with Recurrent High-Grade Glioma

A Phase 0 single center, first in human, open-label study of ascending energy doses of sonodynamic therapy (SDT) utilizing the MRgFUS combined with intravenous ALA to assess safety and efficacy in up to 45 participants with recurrent HGG. …

Sponsor: Nader Sanai
NCT ID: NCT04559685
Sites in Arizona:
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arizona:
  • Massive Bio SYNERGY-AI site — Scottsdale, Arizona
Phase 4 Recruiting Industry

Dabrafenib and/or Trametinib Rollover Study

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the r…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT03340506
Sites in Arizona:
  • Honor Health Research Institute — Scottsdale, Arizona
  • Honor Health Research Institute — Scottsdale, Arizona
Recruiting Academic/Other

Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders

The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate. This study is currently recruiting. There is no cost for visits or study-related ex…

Sponsor: Southwest Autism Research & Resource Center
NCT ID: NCT04322734
Sites in Arizona:
  • Southwestern Research and Resource Center — Phoenix, Arizona
Phase 4 Recruiting Academic/Other

Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions

To find out whether oral antibiotics given after transsphenoidal endoscopic surgery for pituitary adenoma improves sinus and nasal symptoms, reduces the incidence of infection (sinusitis), and helps mucosal healing in the nasal passages.

Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
NCT ID: NCT03014687
Sites in Arizona:
  • Barrow Brain and Spine — Phoenix, Arizona

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20